share_log

Insiders At Merit Medical Systems Sold US$4.4m In Stock, Alluding To Potential Weakness

Insiders At Merit Medical Systems Sold US$4.4m In Stock, Alluding To Potential Weakness

Merit Medical Systems的內部人士出售了440萬美元的股票,暗示潛在的疲軟
Simply Wall St ·  2023/10/15 08:54

The fact that multiple Merit Medical Systems, Inc. (NASDAQ:MMSI) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.

事實上,有多個優點醫療系統公司。納斯達克(Sequoia Capital:MMSI)內部人士在過去一年中拋售了大量股票,可能會讓投資者感到驚訝。在評估內幕交易時,瞭解內幕人士是否在買入通常更有幫助,因為內幕交易可能有各種解釋。然而,如果有幾個內部人士在特定時間段內出售股票,股東們應該更深入地研究一下。

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

儘管我們不認為股東應該簡單地跟蹤內幕交易,但從邏輯上講,你應該關注內部人士是在買入還是賣出股票。

View our latest analysis for Merit Medical Systems

查看我們對Merit醫療系統的最新分析

Merit Medical Systems Insider Transactions Over The Last Year

過去一年的優點醫療系統內幕交易

Over the last year, we can see that the biggest insider sale was by the Founder, Fred Lampropoulos, for US$1.7m worth of shares, at about US$68.43 per share. That means that an insider was selling shares at around the current price of US$64.63. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

在過去的一年裡,我們可以看到,最大的內幕交易是創始人弗雷德·蘭普羅普洛斯以每股68.43美元的價格收購了價值170萬美元的股票。這意味著一位內部人士以目前64.63美元的價格出售股票。我們通常不喜歡看到內幕銷售,但售價越低,我們就越擔心。考慮到這筆交易是以目前的價格進行的,這讓我們有點謹慎,但幾乎不是一個主要的擔憂。

Insiders in Merit Medical Systems didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Merit醫療系統公司的內部人士去年沒有購買任何股票。你可以在下面看到過去12個月(由公司和個人)進行的內幕交易的直觀描述。如果你想知道到底是誰賣了,賣了多少錢,什麼時候賣的,只需點擊下面的圖表!

insider-trading-volume
NasdaqGS:MMSI Insider Trading Volume October 15th 2023
NasdaqGS:MMSI內幕交易量2023年10月15日

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,你會的想懷念這一切嗎?免費內部人士正在收購的成長型公司名單.

Insider Ownership Of Merit Medical Systems

功德醫療系統的內部人所有權

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Merit Medical Systems insiders own about US$85m worth of shares. That equates to 2.3% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

另一種測試公司領導人與其他股東之間一致性的方法是看他們擁有多少股份。我們通常希望看到相當高水平的內部人士持股。優點醫療系統內部人士擁有價值約8500萬美元的股票。這相當於該公司2.3%的股份。雖然這是一個強大但並不突出的內部人持股水準,但這足以表明管理層和小股東之間的某種一致性。

What Might The Insider Transactions At Merit Medical Systems Tell Us?

Merit醫療系統的內幕交易可能告訴我們什麼?

It doesn't really mean much that no insider has traded Merit Medical Systems shares in the last quarter. Our analysis of Merit Medical Systems insider transactions leaves us cautious. The modest level of insider ownership is, at least, some comfort. Of course, the future is what matters most. So if you are interested in Merit Medical Systems, you should check out this free report on analyst forecasts for the company.

上個季度沒有內部人士交易Merit Medical Systems的股票,這並不意味著什麼。我們對Merit Medical Systems內幕交易的分析讓我們保持謹慎。內部人士持股的適度程度至少讓人感到些許安慰。當然了,未來才是最重要的。因此,如果你對Merit Medical Systems感興趣,你應該看看這個免費分析師對該公司的預測報告.

But note: Merit Medical Systems may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:優點醫療系統公司可能不是最值得購買的股票。所以讓我們來看看這個免費高淨資產收益率和低負債的有趣公司名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前只處理公開市場交易和私下處置直接權益,而不處理衍生工具交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論